Can nanotechnology help develop a workable dengue virus vaccine?
UNC School of Medicine researchers Aravinda de Silva, PhD, professor of microbiology and immunology, and Stefan Metz, PhD, are creating a nanoparticle vaccine that in experiments showed increased antibody responses against one serotype of dengue virus. The de Silva group is collaborating with the UNC laboratories of Chris Luft, PhD, (pharmacy and chemistry), Jenny Ting, PhD, (genetics), and Mike Miley,PhD, (pharmacology), as well as Liquidia Pharmaceuticals to use the same nanoparticle platform to develop a vaccine for all four serotypes of the virus.
UNC scientists named to European Union-funded global Zika research ...
The UNC School of Medicine was one of two U.S. institutions named to an international research consortium funded through the European Union’s Horizon 2020 Programme, which invested $49 million in Zika research and vaccine development at more than 20 laboratories in Europe and Brazil.
Antibodies from dengue virus survivors can be used to prevent Zika ...
A new research study from University of North Carolina researchers shows that individuals who have been previously infected with a flavivirus – specifically dengue and Zika viruses – could have antibodies that protect against Zika.
E-cigarette use can alter hundreds of genes involved in airway immu...
The long-term health effects of e-cigarettes remain unknown, but toxicologists at UNC are now uncovering how use of e-cigarettes affect genes involved in upper airway immune defense.
New mouse model to aid testing of Zika vaccine, therapeutics
A research team including Helen Lazear, PhD, assistant professor of microbiology and immunology, has established a mouse model for testing of vaccines and therapeutics to battle Zika virus.